To develop safe vaccines for inducing mucosal immunity to major pulmonary bacterial infections, appropriate vaccine antigens (Ags), delivery systems and nontoxic molecular adjuvants must be considered. Such vaccine constructs can induce Ag-specific immune responses that protect against mucosal infections. In particular, it has been shown that simply mixing the adjuvant with the bacterial Ag is a relatively easy means of constructing adjuvant-based mucosal vaccine preparations; the resulting vaccines can elicit protective immunity. DNA-based nasal adjuvants targeting mucosal DCs have been studied in order to induce Ag-specific mucosal and systemic immune responses that provide essential protection against microbial pathogens that invade mucosal surfaces. In this review, initially a plasmid encoding the cDNA of Flt3 ligand (pFL), a molecule that is a growth factor for DCs, as an effective adjuvant for mucosal immunity to pneumococcal infections, is introduced. Next, the potential of adding unmethylated CpG oligodeoxynucleotide and pFL together with a pneumococcal Ag to induce protection from pneumococcal infections is discussed. Pneumococcal surface protein A has been used as vaccine for restoring mucosal immunity in older persons. Further, our nasal pFL adjuvant system with phosphorylcholine-keyhole limpet hemocyanin (PC-KLH) has also been used in pneumococcal vaccine development to induce complete protection from nasal carriage by Streptococcus pneumoniae. Finally, the possibility that anti-PC antibodies induced by nasal delivery of pFL plus PC-KLH may play a protective role in prevention of atherogenesis and thus block subsequent development of cardiovascular disease is discussed.
serotypes, respectively (PCV13; PREVNAR13, Wyeth Pharmaceuticals Inc., Philadelphia, USA and PPV23; PNEUMOVAX NP, Merck Sharp & Dohme Corp. Inc., Kenilworth, USA). However, these vaccines fail to induce immunity at mucosal surfaces, which is where this pathogen normally resides and from which it often invades the host. To this end, it is important to consider developing the next generation of mucosal vaccines that can elicit anti-pneumococcal SIgA Abs in the upper respiratory tract because it has been shown that these Abs are a central players in immune defense and control dissemination of respiratory pathogenic bacteria such as Streptococcus pneumoniae (4) . Effective mucosal vaccines provide two layers of protective immunity; namely, in both mucosal and systemic tissue compartments. It has been shown that vaccination via the nasal route most effectively induces Ag-specific SIgA and IgG Ab responses in the upper respiratory tract (4) . Because this adjuvant is an essential element for development of nasal vaccines, we have focused our studies on more effective nasal adjuvants that enhance S. pneumoniae-specific SIgA Ab responses. In this review, we will emphasize novel DNA-based adjuvants that target mucosal DCs for development of nasal vaccines that can prevent pneumococcal infections.
THE MUCOSAL IMMUNE NETWORK
The mucosal surfaces of mammalian respiratory, digestive, urinary and reproductive tracts remain healthy despite constantly receiving various stress signals from foods, allergens and pathogenic microorganisms. This is accomplished by a functional mucosal immune system that is composed of a unified network of tissues, lymphoid and mucosa-associated cells, and effector innate (e.g., mucins and defensins) and acquired (e.g., cytokine, chemokine and Ab) molecules. Among these innate and acquired molecules, polymeric IgA Abs play a central role in the mucosal immune system. The common mucosal immune system illustrates the essential concept of defined mucosal inductive and effector lymphoid tissues for eliciting protective mucosal immune responses ( Fig. 1) (5, 6) . The inductive lymphoid tissues, including Waldeyer's ring of tonsils and adenoids (NALT) and Peyer's patches (major gutassociated lymphoid tissue), comprise a mucosaassociated lymphoid tissue network that constantly provides Ag-specific and memory T and B cells to diffuse types of mucosal effector tissues such as the respiratory and digestive systems and other sites where polymeric IgA Abs are produced by localized plasma cells. The polymeric form (mainly dimeric) of the IgA coupled to a secretory component can be transported across epithelial cells (7) . The migration of lymphocytes from inductive to mucosal effector tissues is cellular basis for a common mucosal immune system, this process being directed by expression of adhesion molecules (e.g., integrin a4b7) (8, 9) . In summary, oral or nasal vaccination can elicit mucosal immunity in multiple distant effector sites (Fig. 1) .
Mucosa-associated lymphoid tissue generally consists of three well-organized regions; namely, a subepithelium that contains APCs (most notably DCs), a B-cell zone with germinal centers including follicular DCs, and adjacent T cell areas containing an equal distribution of na€ ıve and memory T cell phenotypes (1, 6) . A follicle-associated epithelium that includes fully-differentiated epithelial cells, termed M, lymphoid and columnar epithelial cells within the epithelium covers the mucosa-associated lymphoid tissue (10) . M cells ingest luminal Ags from the nasal and intestinal mucosa, thus playing a crucial part in initiation of mucosal immune responses. Thus, M cells transport the native Ag to underlying APCs for initial induction of Ag-specific immune responses. Subsequently, Ag-stimulated and memory T and B cell populations egress from mucosal inductive sites via lymphatic drainage, circulate through the bloodstream and finally migrate into mucosal effector tissues, including nasal and intestinal lamina propria regions and glandular exocrine tissues (e.g., salivary, lacrimal and other glands). These mucosal effector sites feature more diffuse connective tissues, in which reside Ag-specific CD4
þ Th 1 and Th2 cells as well as CTLs, which are responsible for cell-mediated immunity/CTL functions, and IgA-committed B lymphocytes, which are responsible for IgA Ab responses (11) . Further, regulatory T cells Fig. 1 . Induction of Ag-specific mucosal SIgA Ab responses via the inductive (NALT/GALT) and effector sites. Ags derived from foreign compounds are presented by APCs beneath mucosal surfaces to na€ ıve lymphocytes within inductive sites of organized mucosal lymphoid tissues, e.g., NALT and gut-associated lymphoid tissue. Activated lymphocytes leave these tissues via draining lymph nodes, reenter mucosal effector tissue sites throughout the body from the circulation, and subsequently establish mucosal immune responses.
and Th17 cells have been identified in the lamina propria of the small intestine; these cells play central roles in protection and/or inflammation within the gut immune system (12) (13) (14) . As a result of this integrated mucosal immune network, appropriate nasal or oral vaccination can induce Ag-specific mucosal immunity in multiple distant effector sites (Fig. 1) . (17) . DC activation, maturation and expansion are regulated by an array of molecules including viral products, bacterial-derived Ags and growth factors, and cytokines (18, 19) . For example, FL, a growth factor, binds to the fms-like tyrosine kinase receptor Flt3/Flk2 and induces dramatic division of DCs in vivo without activating them (20, 21) . It has been shown that systemic injection of FL induces marked increases in numbers of DCs in both mucosal lymphoid (i.e., the intestinal lamina propria, Peyer's patches and mesenteric lymph nodes) and systemic tissues (i.e., spleen) of mice (22) , resulting in induction of oral tolerance (23) . In contrast, it has been shown that FL administration facilitates induction of immune responses after mucosal (23) , systemic (24) , or cutaneous (25) delivery of vaccine Ags. Of interest, the adjuvant activity of FL protein has been confirmed at both the level of Ab production and enhanced cellmediated immunity responses after co-administration of plasmid DNA encoding FL gene with plasmids encoding protein Ags or linked to the Ags themselves (26, 27) . These findings indicate that costly FL protein may now be replaced by using plasmid FL as an adjuvant.
DNA-BASED ADJUVANTS WHICH TARGET MUCOSAL DCs
On the basis of these findings, we hypothesized that FL would be a good candidate for a new-generation mucosal adjuvant that could stimulate DCs in mucosal inductive tissues. To test this possibility, we have employed pFL as a nasal DC-targeting adjuvant for eliciting Ag-specific protective mucosal immunity. Our previous studies showed that OVA-specific mucosal SIgA and systemic IgG and IgA Ab responses are induced in young adult mice by administering weak Ag OVA plus pFL nasally (28) . Of interest, we found that nasal immunization with OVA plus pFL as a mucosal adjuvant preferentially expands CD8
þ DCs in NALT and subsequently induces Ag-specific, Th2-type immune responses mediated by IL-4-producing CD4 þ T cells (Fig. 2) . The strongest expression of this pFLspecific, ampicillin resistant gene occurs in NALT of mice given nasal pFL as a mucosal adjuvant. In this regard, significantly more actual FL protein product was found in NWs from these mice than in NWs from mice given Ag alone or Ag plus pORF as controls. These results suggest that immune cells in NALT are the targets of pFL and that this is where initiation of FL adjuvant function most likely occurs. Although amounts of FL in plasma were also increased, we speculate that this was primarily attributable to exudation from the nasal mucosa because the spleen and other lymph nodes did not express this plasmidspecific gene. Taken together, these findings show that nasally delivered pFL is mainly taken up by NALT, leading to local FL protein production in these tissues, which in turn results in subsequent expansion and activation of DCs in this mucosal inductive site (28) .
The innate immune system is essential for subsequent induction of acquired immunity. Thus, TLRs expressed by innate immune cells, including DCs, specifically recognize pathogen-associated molecular patterns (e.g., LPS, CpG DNA, and flagellin among others) for initiation of innate immunity. It has been shown that pathogen-associated molecular patterns and bacterial/ viral DNA imply a significantly high frequency of unmethylated CpG motifs (29, 30) . Unmethylated CpG motifs are perceived by the innate immune system via TLR9, which is mainly expressed by pDCs and B cells ( Fig. 2) (31) . Thus, unmethylated CpG ODN elicits stimulation and maturation of professional pDCs followed by Ag-specific, CD4
þ Th1 and CD8 þ CTL responses (32, 33) . It has been shown that protective immune responses similar to those triggered by bacterial DNA are induced by synthetic CpG ODN (34) (35) (36) (37) . Because CpG ODN is an effective adjuvant that can target malignancies and reduce allergic responses, CpG motifs are of central importance in TLR9-mediated innate immune responses (38, 39) . Additionally, CpG ODN functions as a potent adjuvant for induction of Agspecific immunity (40) . Indeed, CpG ODN reportedly up-regulates both OVA-specific Ab and cell-mediated immunity responses in mice (41) . Further, toxoid and viral vaccines given with CpG ODN significantly strengthen Ag-specific Ab and CTL responses (42) (43) (44) (45) (46) (47) . Mucosal immunization of CpG ODN plus hepatitis B virus or formalin-inactivated influenza virus surface Ag successfully evokes virus-specific Ab responses in both plasma and external secretions of mice (46, 47) . This CpG ODN motif is also an effective oral adjuvant for both hepatitis B Ag and tetanus toxoid (48) . Further, we have previously shown that nasal immunization with the recombinant protective Ag of the anthrax lethal toxin plus CpG ODN is associated with large amounts of Agspecific mucosal SIgA and strong plasma IgG2a Ab responses (49) . CpG ODN as an adjuvant is quite potent, being capable of eliciting a shift from a predominant Th2-to a Th1-type cytokine response (50) . It has been shown that CpG ODN induces p38 MAP kinase activity, which subsequently promotes activation of NF-k and CREB, which in turn collectively contribute to production of TNF-a, IL-10 and IL-12p70 in a murine macrophage-like cell line (RAW 264.7 cells) (51) . In this regard, the postulated mechanisms for CpG ODN adjuvanticity suggest upregulation by APCs of MAP kinases associated with IL-12 production.
Ideally, novel mucosal vaccines would elicit both CD4
þ Th1-and Th2-type responses because these responses are closely associated with the Ag-specific Ab and CTL responses that provide protective immunity against bacterial and viral infections. Further, a balanced Th1-and Th2-type cytokine response would evade exaggerated Th1-cytokine mediated inflammation or hyper Th2-cytokine-related allergic responses. Because CpG ODN preferentially provokes CD4 þ Th1-type, cytokine-mediated immunity (49) , whereas pFL favors induction of Th2-type cytokine responses (28) , it was intriguing to assess whether a combination of pFL and CpG ODN as a mucosal DC targeting adjuvant would induce an enhanced but more balanced immune response. Indeed, our previous study showed that nasal immunization with OVA plus a combination of pFL and CpG ODN upregulates anti-OVA mucosal and systemic Ab responses similarly to those elicited by a single nasal adjuvant regimen (either pFL or CpG ODN alone) (Fig. 2) (52) . Notably, pFL and CpG ODN as a combined nasal adjuvant supports prolonged (more than 25 weeks) and strong OVA-specific Ab responses (52) . Of importance, nasal immunization of aged (2-year-old) mice with OVA plus combined adjuvant, reportedly results in significantly stronger OVA-specific SIgA Ab responses in mucosal secretions, these responses being essentially equivalent to those seen in identically immunized, young adult mice (52) .
PROTECTIVE IMMUNE RESPONSES TO PspA THAT EMPLOY THE pFL/CpG ODN ADJUVANT S. pneumoniae have more than 90 capsular serotypes based on the structure of the polysaccharide capsule, which is a major virulence factor (53) . It is known that the capsule enables S. pneumoniae to avoid entrapment by external secretions in the nasal cavity and the upper respiratory tract, and also protection of pneumococci from opsonization and phagocytosis (54) . A PPV23 (PNEUMOVAX NP) for adults and PCV7, 10, 13 (PREVNAR 13) for children have been developed for public use and are delivered by intramuscular injection (55) (56) (57) . It has been shown that the polysaccharide vaccine PNEUMOVAX NP fails to elicit adequate T cell-dependent immune responses. Further, Fig. 2 . Nasal DC-targeting adjuvant systems using pFL and/or CpG ODN for induction of protective mucosal immunity. Nasal pFL as mucosal adjuvant preferentially expands CD8 (62, 63) . In this regard, we have shown that nasal delivery of pFL as a mucosal adjuvant enhances anti-PspA SIgA Ab responses in the lungs (64) and nasal cavities (4) of young adult mice that inhibit S. pneumoniae colonization (Fig. 3 ). An IgA deficient (IgA À/À ) mouse model has provided additional direct evidence of the importance of anti-PspA SIgA Abs for prevention of bacterial colonization of the nasal cavity. Despite strong PspA-specific IgG Ab responses, significantly high numbers of S. pneumoniae CFUs have been detected in the nasal cavities of IgA À/À mice given nasal PspA plus pFL. In contrast, wild type IgA þ/þ mice given nasal PspA plus pFL were found to harbor essentially no S. pneumoniae in the nasal mucosa. Finally, a PspA-based vaccine containing pFL as nasal adjuvant diminishes pre-existing S. pneumoniae in the nasal mucosa (4). These findings suggest that a PspAbased nasal vaccine that induces specific SIgA Abs could play an indispensable role in regulation of S. pneumoniae colonization of the upper respiratory tract.
We were the first to establish that combined pFL and CpG ODN as nasal adjuvant is a good strategy by using the weak Ag OVA in aged mice (52) . Thus, this double adjuvant system could facilitate development of practical vaccines for older persons; the current licensed vaccines often fail to induce protective vaccine-Ag-specific immunity in this immunocompromised cohort. In this regard, we have examined whether this double adjuvant system is capable of supporting PspA-specific SIgA Ab responses in the upper respiratory tract and thus preventing nasal S. pneumoniae infection. Nasal vaccination with PspA plus a combination of pFL and CpG ODN more strongly induces of PspA-specific mucosal SIgA and plasma IgG Ab responses in both young adult and aged mice than vaccination without these adjuvants (Fig. 4) . Of importance, although young adult mice that have been given PspA and pFL or CpG ODN nasally display strong PspA-specific Ab responses, the same single adjuvant strategies reportedly do not elicit antiPspA mucosal SIgA and plasma IgG Ab responses (65) . When CD4 þ T cell responses were assessed, significantly stronger PspA-induced Th1-and Th2-type cytokine responses were observed in NALT and cervical lymph nodes of aged mice given nasal PspA plus pFL and CpG ODN than in those of mice that did not receive these adjuvants. Further, mucosal tissues of these aged mice contained greater numbers of mature-type CD11b-or CD8-expressing DCs. Of importance, aged mice immunized nasally with PspA plus pFL and CpG ODN showed protection against nasal S. pneumoniae colonization. In contrast, both young adult and aged mice given nasal PspA alone failed to show sufficient protection after nasal infection with S. pneumoniae. Similarly, aged mice given PspA-based vaccine containing either pFL or CpG ODN only also failed to clear bacterial colonization in NPs and NWs. These results clearly show that a nasal PspA-based vaccine containing a combined DNA adjuvant offer significant potential for protection of older persons against S. pneumoniae. 
A NOVEL S. PNEUMONIAE MUCOSAL VACCINE CONSISTING OF pFL PLUS PC CONJUGATED WITH PROTEIN
Choline is a known nutritional requirement for a wide variety of pathogenic agents, including pneumococci, in which PC is biosynthesized from choline and adenosine triphosphate and incorporated into teichoic acid and lipoteichoic acid to create a cell wall component (66) . PC is recognized as an immunodominant epitope of a structural cell wall component of S. pneumoniae (67, 68) . On the basis of these findings, we have postulated that PC conjugated with a carrier protein such as KLH (PC-KLH) could be used as a candidate Ag for development of potential protective vaccines against pneumococcal infections. Young adult mice given nasal PC-KLH plus pFL reportedly have large amounts of PCspecific IgM and IgA Abs in airway secretions and plasma ( Fig. 5) (69) . In addition, S. pneumoniae colonization is significantly inhibited in the nasal cavities and lungs of mice immunized nasally with pFL plus PC-KLH (Fig. 6) (69) . In contrast, mice given pORF as a control adjuvant or no adjuvant (PC-KLH alone) showed weak anti-PC Ab responses and were not protected against S. pneumoniae colonization (69) . Although it has been reported that hapten conjugated with KLH induces significant anti-hapten Ab responses without adjuvant (70) , our studies have shown that a nasal adjuvant is required for induction of protective immunity to S. pneumoniae infection. It has been shown that TEPC15 myeloma protein (T15) Ab, which is a mouse anti-PC mAb, reacts specifically with AB1-2 mAb (71). This T15 idiotype Ab is reportedly the most effective Ab for prevention of pneumococcal infection (72) . Ab-binding to PC was found to be significantly blocked in the presence of the free hapten PC in a dose-dependent manner when the specificity of IgA and IgM Abs elicited by nasal pFL with PC-KLH for PC-binding was determined (69) . Further, these PC-specific Abs bind to AB1-2 mAbs in the same fashion (69) . These findings indicate that mucosal and systemic PC-specific Abs induced by nasal pFL plus PC-KLH vaccination are most likely T15 idiotype Abs. T15 idiotype Abs are mainly produced by peritoneal CD5
þ B (B-1 B) cells (73) . Additionally, B-1 B cells have been shown to produce Abs in response to PC, LPS, phosphatidylcholine, as well as to undefined determinants expressed by both E. coli and Salmonella (74) . It has been shown that B-1 B cells are an important source of IgA Abs against cell wall protein Ags of commensal bacteria occurring in the enteric mucosal tissues (75, 76) . Indeed, we have shown that nasal delivery of TNP-LPS and cholera toxin as adjuvant enhanced mucosal IgA Ab production by B-1 B cells in submandibular glands and NPs (77) . Since nasal PC-KLH plus pFL vaccine resulted in increased numbers of B-1 B cells in the lungs and NPs, it is possible that anti-PC IgA and IgM Abs are produced by these mucosal B-1 B cells.
Taken together, nasal vaccination with PC-KLH and pFL induced mostly T15-like PC-specific IgA and IgM Abs in the upper respiratory tract and this response was associated with reduced S. pneumoniae colonization of these tissues. We are currently assessing NWs for the amino acid sequence of PC-specific IgA and IgM Abs induced by nasal delivery of PC-KLH plus pFL to determine whether these Abs are of the T-15 idiotype. Use of our nasal adjuvant system may facilitate development of a PC-based nasal vaccine that more effectively prevents S. pneumoniae infection than currently available preparations. PC-based vaccines reportedly possess a major additional benefit in that it has been shown that PC-specific Abs are central players in protection against atherogenesis and development of cardiovascular disease (78) (79) (80) (81) . Thus, upregulation of natural Abs to PC by active vaccination with PC or PC-associated bacteria as Ag would reduce development of atherosclerosis by mechanisms that include inhibition of foam-cell formation and an anti-inflammatory effect against inflammatory reactions in atherosclerotic lesions. Further, it has been reported that anti-PC IgG Abs exert atheroprotective effects by inhibiting expression of platelet-activating factor-induced adhesion molecules (e.g., ICAM-1 and VCAM-1) on endothelial cells in vitro (81) . These findings indicate that anti-PC plasma IgG Abs induced by nasal delivery of PC-KLH plus pFL most likely play a protective role against development of atherosclerosis as well as preventing pneumococcal infection. We are currently examining atheroprotective outcomes of nasal PC-KLH plus pFL vaccination by investigating the severity of intra-aortic plaque accumulation in an atherosclerosis mouse model (apolipoprotein E-deficient mice). Given that PC-based pneumococcal vaccine provides both atheroprotective effects and immunity to pneumococci, it would be interesting to ascertain whether this vaccine system is able to protect older persons, who are more susceptible to infection. It has been shown that classical mucosal adjuvants, including cholera toxin and other nasal adjuvants including pFL and CpG ODN alone, fail to induce protective mucosal immunity in aged mice (52) . In this regard, it would be important to test whether a combination of pFL and CpG ODN enhances anti-pneumococcal immunity in older persons when employed as a nasal adjuvant for PC-based vaccines.
CONCLUSIONS
S. pneumoniae, a potent bacterial pathogen, colonizes the upper respiratory tracts of hosts, resulting in significant morbidity and death. Ideal vaccines for preventing pneumococcal infections would prevent both colonization and growth of this pathogen on mucosal surfaces. In this regard, we have shown that nasal delivery of S. pneumoniae-derived Ags (PspA, PC-KLH) with the innate adjuvant molecules pFL and/or CpG ODN enhance Ab responses, thus preventing pneumococcal infection (Fig. 7) . Further, we have provided evidence that a nasal PC-KLH plus pFL vaccine may have antiatherosclerotic effects (Fig. 7) . Because, especially when formulated as a nasal vaccine component, pFL as a mucosal adjuvant also induces carrier protein (KLH)-specific Ab responses that are potentially problematic for human use, future PC-based vaccines would preferably use protein carriers other than KLH. Indeed, it has been shown that KLH can induce Ag-non-specific, cell-mediated and humoral Ab responses (82) . It has also been reported that KLH immunization has mild to moderate adverse effects (82) . In the future, it would be interesting to elicit both T celldependent and independent Ab responses to S. pneumoniae by employing PspA as a carrier protein for PC. Taken together, it should become possible to develop safer and more effective mucosal vaccines to bacterial and viral pathogens by using appropriate mucosal DC-targeting adjuvants such as DNA-based nasal adjuvants. Fig. 7 . A novel type of pneumococcal vaccine with DC-targeting DNA-based nasal adjuvant. Nasal delivery of PC-KLH plus pFL results in inhibition of S. pneumoniae colonization of the upper and lower respiratory tracts, concurrent with expansion of mucosal DCs and enhancement of anti-PC Ab production. In addition, this nasal vaccination increased the numbers of B-1 B cells producing the T15 idiotype in mucosal effector tissues. Use of a nasal PC-KLH plus pFL vaccine, which may also exhibit anti-atherosclerotic effects, should now be considered.
